A UK university has developed synthetic antibody technology that offers benefits over traditional antibodies. The university is looking for industrial end-user partners to validate this synthetic antibody technology as part of a proposal to a UK funding competition. Preference is to partner with companies that work with biomarkers, such as the cardiac biomarker troponin. It is envisaged that the partnership will take the form of a research cooperation agreement.
Antibodies are a very important tool in both industry and academia, particular in the life sciences sectors where they are used for the detection of biomolecules. This is especially important in the field of diagnostics. However despite their importance and widespread use traditional antibodies have several flaws. They are difficult and expensive to produce in large quantities, it is difficult to retain consistency between batches and they require the use of animals in their production.
A UK university has developed a synthetic antibody technology, molecularly imprinted polymers (MIPs), that overcome these drawbacks. Molecular imprinting technology is versatile and it is possible to tailor the polymer for specific targets; meaning it is possible to detect a wide range of biological targets from small ions to larger proteins, bacteria and cells. This methodology removes the requirement for the use of animals, increases batch reproducibility and reduces cost.
The university is developing this synthetic antibody technology for the area of medical diagnostics and are submitting a proposal to a UK funding competition, CRACK IT, to allow further development for this area of application. The preference is to look at biomarkers, such as the cardiac biomarker troponin.
The university is looking for companies that would be potential end users for this synthetic antibody technology, e.g. companies that carry out diagnostic immunoassay screening, to take part in this proposal. The company would be asked to use this technology alongside their normal antibodies to validate their performance and provide feedback to the university to enable further development. Preference is for companies that work with biomarkers, especially the cardiac biomarker troponin as this is of particular interest in relation to the proposal but other biomarkers are also being considered.
It is expected that the partnership will take the form of a research cooperation agreement. The deadline for the funding competition is November 2017 so EOIs should be received before 15th September 2017.
- Type of partner sought: The UK university is looking for industrial partners that have expertise in the use of traditional antibodies in the medical diagnostics space and who would be potential end users of the university's synthetic antibody technology.
Companies that work with biomarker and in particular the cardiac biomarker troponin are especially of interest.
The company should be able to provide feedback on the performance of the synthetic antibody technology compared with traditional antibodies in their assay systems and procedures.
- Specific area of activity of the partner: The UK university is looking for companies that would be potential end users of this synthetic antibody technology such as those that carry out medical diagnostic immunoassay screening. In particular they are interested in companies that work with biomarkers such as the cardiac biomarker troponin. The company would be required to test the university's synthetic antibody technology alongside their standard antibodies to compare and contrast performance and provide feedback to the university.
It is envisaged that the partnership will take the form of a research cooperation agreement.
30/10/2018 - Ocean Energy Europe 2018